NDA 221198 · Mirum
Atebrioz
Zilurgisertib Fumarate · Oral
NovelPriority reviewOrphanCDER novel approval, Sep 25, 2026: To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Sep 25, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 25, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
- ATEBRIOZ · ZILURGISERTIB FUMARATE EQ 25MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Zilurgisertib" as an intervention, any sponsor and status, largest first.
Incyte CorporationIncyte (INCY)
NCT05090891 · 98 participants (planned) · Start May 5, 2022 · Primary completion Jul 30, 2027
Drug: INCB000928; Placebo · For: Fibrodysplasia Ossificans Progressiva (FOP)
Sites: Rochester, Minnesota; Philadelphia, Pennsylvania; Buenos Aires, Argentina · 24 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Itraconazole or Rifampin on Zilurgisertib Pharmacokinetics When Administered Orally in Healthy Participants.
Yang YO, Gong X, Wang P, et al. · Clin Pharmacol Drug Dev 2025 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Pharmacokinetics of Zilurgisertib With and Without Food from Single and Multiple Ascending Dose Phase 1 Studies in Healthy Adults.
Yang YO, Gong X, Getsy J, et al. · Eur J Drug Metab Pharmacokinet 2025 · Clinical Trial, Phase I, Randomized Controlled Trial
- Evaluation of clinical cardiac safety of zilurgisertib, an activin receptor-like kinase-2 (ALK2) inhibitor, in healthy participants.
Yang YO, Yang H, Liu X, et al. · Clin Pharmacol Drug Dev 2026 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Mirum
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.